Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal
Stockholm, March 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ) protofibril[1] antibody lecanemab (generic name, U.S. brand name: LEQEMBI™) in people living with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) using data from the Phase 3 clinical study, Clarity AD, by applying a validated disease simulation model, AD Archimedes Condition Event (AD ACE) model[2][,][3][,][4] from the